Xeris Biopharma Holdings, Inc. (XERS)
8.48
-0.12
(-1.40%)
USD |
NASDAQ |
Aug 28, 16:00
8.475
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Price to Book Value
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| June 29, 2026 | 102.65 |
| June 26, 2026 | 101.99 |
| June 25, 2026 | 98.14 |
| June 24, 2026 | 98.14 |
| June 23, 2026 | 95.49 |
| June 22, 2026 | 91.51 |
| June 18, 2026 | 92.18 |
| June 17, 2026 | 91.51 |
| June 16, 2026 | 91.51 |
| June 15, 2026 | 91.25 |
| June 12, 2026 | 90.05 |
| June 11, 2026 | 91.91 |
| June 10, 2026 | 88.99 |
| June 09, 2026 | 86.21 |
| June 08, 2026 | 82.76 |
| June 05, 2026 | 81.96 |
| June 04, 2026 | 81.57 |
| June 03, 2026 | 78.12 |
| June 02, 2026 | 79.58 |
| June 01, 2026 | 80.50 |
| May 29, 2026 | 81.70 |
| May 28, 2026 | 83.82 |
| May 27, 2026 | 82.63 |
| May 26, 2026 | 83.02 |
| May 22, 2026 | 82.10 |
| Date | Value |
|---|---|
| May 21, 2026 | 84.62 |
| May 20, 2026 | 82.63 |
| May 19, 2026 | 78.51 |
| May 18, 2026 | 79.71 |
| May 15, 2026 | 82.76 |
| May 14, 2026 | 84.62 |
| May 13, 2026 | 85.28 |
| May 12, 2026 | 83.02 |
| May 11, 2026 | 81.43 |
| May 08, 2026 | 86.60 |
| May 07, 2026 | 87.93 |
| May 06, 2026 | 84.48 |
| May 05, 2026 | 82.63 |
| May 04, 2026 | 84.09 |
| May 01, 2026 | 83.29 |
| April 30, 2026 | 81.23 |
| April 29, 2026 | 79.84 |
| April 28, 2026 | 80.77 |
| April 27, 2026 | 81.17 |
| April 24, 2026 | 80.24 |
| April 23, 2026 | 78.91 |
| April 22, 2026 | 80.11 |
| April 21, 2026 | 78.12 |
| April 20, 2026 | 82.89 |
| April 17, 2026 | 84.48 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Zevra Therapeutics, Inc. | 3.153 |
| Aclaris Therapeutics, Inc. | 6.745 |
| ANI Pharmaceuticals, Inc. | 2.802 |
| Corcept Therapeutics, Inc. | 17.41 |
| Veru, Inc. | 1.577 |
Price to Book Value Related Metrics
| PS Ratio | 4.476 |
| Price to Free Cash Flow | 26.97 |
| Price | 8.48 |
| Earnings Yield | -1.21% |
| Market Cap | 1.472B |
| Operating PE Ratio | 41.03 |
| Normalized PE Ratio | 380.27 |